Ponatinib is a multi-targeted tyrosine kinase inhibitor that is active against T315I and other BCR-Abl mutants.  It inhibits all tested BCR-Abl mutants in cellular and biochemical assays, suppresses BCR-Abl(T315I)-driven tumor growth in mice, and completely abrogates resistance in cell-based mutagenesis screens.